| CRENESSITY |
CRENESSITY |
92%
|
In addition, CRENESSITY is distributed by one specialty pharmacy provider. |
| SPECIALTY-PHARMACY-PROVIDERS |
SPECIALTY-PHARMACY-PROVIDERS |
92%
|
We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors. |
| ETON |
Eton Pharmaceuticals, Inc. |
72%
|
cules, peptides, proteins, antibodies, and gene therapy. We launched INGREZZA ® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of tardive dyskinesia in May 2017 and for th… |
| ETON |
Eton Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: cules, peptides, proteins, antibodi… |
| LXEO |
Lexeo Therapeutics, Inc. |
72%
|
Reciprocal relationship from LXEO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a s… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ORAN… |
| ORANY |
ORANY |
72%
|
ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202… |
| SLNO |
Soleno Therapeutics, Inc. |
72%
|
Reciprocal relationship from SLNO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from SLNO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from SLNO g… |
| SLNO |
Soleno Therapeutics, Inc. |
72%
|
oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V… |
| SNYNF |
Sanofi |
72%
|
oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from NBIX graph: oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exe… |
| SPRB |
Spruce Biosciences, Inc. |
72%
|
Reciprocal relationship from SPRB graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from SPRB graph: her jurisdictions, all of which could seriously harm our business. 85 Table … |
| STQN |
Strategic Acquisitions, Inc. |
72%
|
INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a… |
| STQN |
Strategic Acquisitions, Inc. |
72%
|
Reciprocal relationship from STQN graph: Reciprocal relationship from NBIX graph: INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates enco… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from NBIX graph: ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in dis… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
Reciprocal relationship from VYGR graph: d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affe… |
| XENE |
Xenon Pharmaceuticals Inc. |
72%
|
Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will… |
| XENE |
Xenon Pharmaceuticals Inc. |
72%
|
ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202… |
| DIURNAL-GROUP |
DIURNAL-GROUP |
62%
|
oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V… |
| LICENSE-AGREEMENTS-NXERA-PHARMA-UK-LIMITED |
LICENSE-AGREEMENTS-NXERA-PHARMA-UK-LIMITED |
62%
|
erating lease cost $ 15.4 $ 16.5 Sublease income ( 0.9 ) ( 0.9 ) Net operating lease cost $ 14.5 $ 15.6 Cash paid for amounts included in the measurement of operating lease liabilities $ 12.7 $ 9.3 M… |
| MITSUBISHI-TANABE-PHARMA-CORPORATION |
MITSUBISHI-TANABE-PHARMA-CORPORATION |
62%
|
cules, peptides, proteins, antibodies, and gene therapy. We launched INGREZZA ® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of tardive dyskinesia in May 2017 and for th… |
| NEUROCRINE-GROUP-LIMITED |
NEUROCRINE-GROUP-LIMITED |
62%
|
oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V… |
| NXERA-PHARMA-UK-LIMITED |
NXERA-PHARMA-UK-LIMITED |
62%
|
INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a… |
| OPERATIONS-NEUROCRINE-BIOSCIENCES-INC |
OPERATIONS-NEUROCRINE-BIOSCIENCES-INC |
62%
|
68 NEUROCRINE BIOSCIENCES, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. Business Overview and Summary of Significant Accounting Policies Nature of Operations Neurocrine Biosciences, Inc. an… |
| SOSEI-HEPTARES-TAKEDA-PHARMACEUTICAL-COMPANY-LIM |
SOSEI-HEPTARES-TAKEDA-PHARMACEUTICAL-COMPANY-LIM |
62%
|
INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a… |
| TANABE-PHARMA-CORPORATION |
TANABE-PHARMA-CORPORATION |
62%
|
oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V… |
| TEVA |
Teva Pharmaceutical Industries Limited |
62%
|
Reciprocal relationship from TEVA graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TEVA g… |
| TEVA-PHARMACEUTICALS-INDUSTRIES |
TEVA-PHARMACEUTICALS-INDUSTRIES |
62%
|
ric patients four years of age and older with classic CAH. We have also established our commercial team and hired our U.S. sales force for CRENESSITY. The successful commercial launch of CRENESSITY d… |
